Pharmacogenetic Study of the medication Ondansetron in Alcohol Use Disorder
Brief Description Of Study
The primary study objective is to determine the efficacy of ondansetron (0.33 mg twice daily) administered orally for a period of 16 weeks in reducing risky drinking among currently drinking African American subjects with Alcohol Use Disorder who have selected genotypes at the serotonin transporter and receptor genes. The secondary objective is to assess the safety and tolerability of ondansetron in subjects with alcohol use disorder who have selected genotypes at the serotonin transporter and receptor genes. The study will last approximately 20 weeks including a screening visit, 11 regular study visits, and a follow-up visit.